Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of early bone loss after total hip arthroplasty
ChiCTR-PRC-13003088Phase 4Completed
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zoledronic acid in Aseptic loosening (AL) and osteoporosis (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Bone mineral density. Started Sep 2014; status: completed.
02
Drugs
zoledronic acid
03
Conditions
Aseptic loosening (AL)osteoporosis
Beyond the preview
Go deeper on ChiCTR-PRC-13003088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-13003088.